BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nemtabrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nemtabrutinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06572618-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT06572618)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Nemtabrutinib With Rituximab f
 or the Treatment of Patients With Mantle Cell Lymphoma\nEstimated primary 
 completion: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06572618
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734610-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Nemtabrutinib: Phase 1 readout est. (NCT07734610)
DESCRIPTION:Nemtabrutinib\, phase 1.\nStudy: A Clinical Trial of Nemtabruti
 nib in Participants With Severe Kidney Disease (MK-1026-027)\nEstimated pr
 imary completion: 1 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07734610
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347225-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nemtabrutinib: Phase 1 readout est. (NCT05347225)
DESCRIPTION:Nemtabrutinib\, phase 1.\nStudy: A Study of Nemtabrutinib (MK-1
 026) in China Participants With Relapsed or Refractory Hematologic Maligna
 ncies (MK-1026-005)\nEstimated primary completion: 30 April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05347225
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624554-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05624554)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
 CLL/SLL) Without TP53 Aberrations (MK-1026-008\, BELLWAVE-008)\nEstimated 
 primary completion: 19 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05624554
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03162536-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270917
DTEND;VALUE=DATE:20270918
SUMMARY:Nemtabrutinib: Phase 1/2 readout est. (NCT03162536)
DESCRIPTION:Nemtabrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Ref
 ractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)\nEstimated prim
 ary completion: 17 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03162536
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557056-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07557056)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic L
 ymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nemtabrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07557056
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04728893-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT04728893)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Efficacy and Safety of Nemtabr
 utinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-00
 3)\nEstimated primary completion: 4 January 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04728893
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458297-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT05458297)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combinati
 on in Participants With Aggressive and Indolent B-cell Malignancies (MK-21
 40-006)\nEstimated primary completion: 17 May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05458297
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863402-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT06863402)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformati
 on\, Diffuse Large B-cell Lymphoma Subtype\nEstimated primary completion: 
 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nemtabru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06863402
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464210-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07464210)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Nemtabrutinib\, Bortezomib\, a
 nd Rituximab for WM\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07464210
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194980-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20291020
DTEND;VALUE=DATE:20291021
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07194980)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/
 Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstima
 ted primary completion: 20 October 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07194980
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic L
 ymphocytic Leukemia\nEstimated primary completion: 1 December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nemtabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583810-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300925
DTEND;VALUE=DATE:20300926
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07583810)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Non-covalent BTK Inhibitor Nem
 tabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for 
 the Treatment of Marginal Zone Lymphoma\nEstimated primary completion: 25 
 September 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nemta
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07583810
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796373-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07796373)
DESCRIPTION:Nemtabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Le
 ukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pi
 rtobrutinib and Previously Treated With a BCL2 Inhibitor\nEstimated primar
 y completion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07796373
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673367-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Nemtabrutinib: Phase 2 readout est. (NCT07673367)
DESCRIPTION:Nemtabrutinib\, phase 2.\nStudy: Nemtabrutinib With CAR T Thera
 py in Relapsed/Refractory Mantle Cell Lymphoma\nEstimated primary completi
 on: 31 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nem
 tabrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07673367
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947851-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20320601
DTEND;VALUE=DATE:20320602
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT05947851)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) i
 n Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemi
 a/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).\nEstima
 ted primary completion: 1 June 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05947851
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136559-11239@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20320907
DTEND;VALUE=DATE:20320908
SUMMARY:Nemtabrutinib: Phase 3 readout est. (NCT06136559)
DESCRIPTION:Nemtabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choi
 ce of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic L
 eukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
 \nEstimated primary completion: 7 September 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nemtabrutinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06136559
URL:https://assetmemo.bio/drug/nemtabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
